The United States of America, As Represented by the Secretary, Department of Health and Human Services

Florida International University

Massachusetts Institute of Technology

Icahn School of Medicine at Mount Sinai

Marc Ferrer-Alegre

Wei Ping Zheng

Juan Jose Marugan

Noel Terrence Southall

Jingbo Xiao

Catherine Chen

Todd A Thorsen

Kapil Bharti

Samarjit Patnaik

Yiannis A Ioannou

Arvydas Maminishkis

Sheldon S Miller

Irina Agoulnik

Alexander Agoulnik

Patricia Dranchak

Johanna Bobrow

Min Jae Song

Janine Davis

Mercedes Taylor

Raul Rolando Calvo

Yen-Ting Tung

Seameen Dehdasthi

David Walsh

Sam Michael

Fannie Chen

Christina Zook

Molly Elizabeth Boutin

Wei Zheng

Noel Southall

Yiannis Ioannou

An in vitro tissue plate may include a well plate, a fluidic plate disposed on a bottom surface of the well plate, and a media manifold disposed on a bottom surface of the fluidic plate. The well plate may have at least two wells, including a tissue well and a waste well. The fluid plate may include a fluid channel extending between and fluidly connecting the tissue well to the waste well. The media manifold may include a one or more media outlets fluidly connected to the fluid channel. A tissue layer may be deposited in the tissue well. The tissue layer may include human cells such as neurovascular cells.

In vitro tissue plate

Methods and compositions for treating lysosomal storage disorders are disclosed. The methods involve administering a genus of benzenesulfonamides, particularly N-[3-(aminosulfonyl)phenyl]-benzamides and heteroarylamides. A genus of suitable compounds is shown in formula 1: 

Benzenesulfonamide upregulators of NPC1 for Neimann-Pick disease and other lysosomal storage disorders

Disclosed are modulators of the human relaxin receptor 1, for example, of formula (I), wherein A, R, and Rare as defined herein, that are useful in treating mammalian relaxin receptor 1 mediated facets of human health, e.g., cardiovascular disease. Also disclosed is a composition comprising a pharmaceutically suitable carrier and at least one compound of the disclosure, and a method for therapeutic intervention in a facet of mammalian health that is mediated by a human relaxin receptor 1. 

Modulators of the relaxin receptor 1

Disclosed are modulators of the human relaxin receptor 1, for example, of formula (I), wherein A, R, and Rare as defined herein, that are useful in treating mammalian relaxin receptor 1 mediated facets of human health, e.g., cardiovascular disease. Also disclosed is a composition comprising a pharmaceutically suitable carrier and at least one compound of the disclosure, and a method for therapeutic intervention in a facet of mammalian health that is mediated by a human relaxin receptor 1.

Growing community of inventors

Potomac, MD, United States of America

Marc Ferrer-Alegre